title: QSARs for 6-azasteroids as inhibitors of human type 1 5alpha-reductase: prediction of binding affinity and selectivity relative to 3-BHSD.
abstract: Quantitative structure-activity relationships (QSARs) are developed to describe the ability of 6-azasteroids to inhibit human type 1 5alpha-reductase. Models are generated using a set of 93 compounds with known binding affinities (K(i)) to 5alpha-reductase and 3beta-hydroxy-Delta(5)-steroid dehydrogenase/3-keto-Delta(5)-steroid isomerase (3-BHSD). QSARs are generated to predict K(i) values for inhibitors of 5alpha-reductase and to predict selectivity (S(i)) of compound binding to 3-BHSD relative to 5alpha-reductase. Log(K(i)) values range from -0.70 log units to 4.69 log units, and log(S(i)) values range from -3.00 log units to 3.84 log units. Topological, geometric, electronic, and polar surface descriptors are used to encode molecular structure. Information-rich subsets of descriptors are identified using evolutionary optimization procedures. Predictive models are generated using linear regression, computational neural networks (CNNs), principal components regression, and partial least squares. Compounds in an external prediction set are used for model validation. A 10-3-1 CNN is developed for prediction of binding affinity to 5alpha-reductase that produces root-mean-square error (RMSE) of 0.293 log units (R(2) = 0.97) for compounds in the external prediction set. Additionally, an 8-3-1 CNN is generated for prediction of inhibitor selectivity that produces RMSE = 0.513 log units (R(2) = 0.89) for the external prediction set. Models are further validated through Monte Carlo experiments in which models are generated after dependent variable values have been scrambled.
authors.affiliation: 152 Davey Laboratory, Department of Chemistry, The Pennsylvania State University, University Park, PA 16802, USA.
authors.forename: G A
authors.initials: GA
authors.lastname: Bakken
authors.forename: P C
authors.initials: PC
authors.lastname: Jurs
mesh_terms: D001378:Azasteroids / Q000737:chemistry* / Q000494:pharmacology*; D042944:Cholestenone 5 alpha-Reductase; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D008954:Models, Biological; D009010:Monte Carlo Method; D009097:Multienzyme Complexes / Q000378:metabolism; D010088:Oxidoreductases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011375:Progesterone Reductase / Q000378:metabolism; D021281:Quantitative Structure-Activity Relationship; D013251:Steroid Isomerases / Q000378:metabolism
chemical_list: C021425:3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomerase; D001378:Azasteroids; D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D010088:Oxidoreductases; D011375:Progesterone Reductase; D042944:Cholestenone 5 alpha-Reductase; D013251:Steroid Isomerases